Key facts
- It has raised $7.1M; the latest was Later Stage VC ($1.1M) in Dec 2024.
- Notable investors include Venture Kick, Innosuisse, Kickfund, BioInnovation Institute, BaseLaunch — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for FimmCyte
- ·The full record, as it builds
Funding rounds
No funding rounds for FimmCyte are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FimmCyte
Operator of a biotechnology company intended to accelerate the path toward an endometriosis cure. The company is developing treatments to address healthcare requirements and novel ideas to advance women's health, enabling women to take control of their health and address their unmet medical needs.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Employees
- 5
- Website
- fimmcyte.com/
- Ownership
- Privately Held (backing)
FimmCyte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FimmCyte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FimmCyte in its N-PORT filings yet. We sweep new filings monthly.